ライフサイエンスコーパス: stimulating agent

1 ogic; normalized by treatment with erythroid-stimulating agent).

2 nfection rate, and dose of an erythropoiesis-stimulating agent.

3 l gene expression response regardless of the stimulating agent.

4 ickly even in the continuous presence of the stimulating agent.

5 y complex (MHC) class II tetramers (TMrs) as stimulating agents.

6 eration of more focused and effective immune stimulating agents.

7 urkat T cell line upon treatment with T cell stimulating agents.

8 , and de novo prescription of erythropoiesis-stimulating agents.

9 ponsiveness to treatment with erythropoiesis-stimulating agents.

10 onse to or are ineligible for erythropoiesis-stimulating agents.

11 rrently in clinical trials as erythropoiesis-stimulating agents.

12 dity and mortality related to erythropoiesis stimulating agents.

13 ation, and adverse effects of erythropoiesis-stimulating agents.

14 on and trafficking, and novel erythropoiesis-stimulating agents.

15 the absence of transfusion or erythropoiesis-stimulating agents.

16 vs seven [3%]; p=0.003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0.017).

17 We showed that the RYR-stimulating agent 4-chloro-m-cresol (4CmC) induced Ca(2+

18 Erythropoiesis stimulating agent administration in sTBI is associated w

19 Erythropoiesis-stimulating agent administration to patients with cancer

20 Erythropoietin (EPO) an erythropoietic stimulating agent also exerts effects on other cell syst

21 we determined perturbations of an erythroid-stimulating agent and exercise training to examine if an

22 Erythropoiesis-stimulating agents and blood transfusion were also assoc

23 In view of the expense of erythropoiesis stimulating agents and the uncertainty of the safety of

24 e because of the therapy with erythropoiesis-stimulating agents and/or iron or despite such a therapy

25 aluated to include infection, erythropoiesis-stimulating agents, and blood transfusion.

26 l children), reduced need for erythropoiesis-stimulating agents, and lower risk of blood-borne virus

27 e-targeted ventilation, early erythropoiesis-stimulating agents, and prophylactic ethamsylate were as

28 ch for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agent

29 away from the liberal use of erythropoiesis-stimulating agents as the main treatment for the anemia

30 complications, in the use of erythropoiesis-stimulating agents at hospital discharge, in the inciden

31 requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a rand

32 nd resulted in lower doses of erythropoiesis-stimulating agent being administered.

33 mbination of iron therapy and erythropoiesis-stimulating agents can improve anemia in many patients.

34 proliferation profile in response to B cell-stimulating agents compared with B cells from unmanipula

35 Addition of an erythropoiesis-stimulating agent could improve response rate.

36 ompared with the conventional erythropoiesis-stimulating agent darbepoetin alfa, are unknown.

37 uggest that administration of erythropoiesis-stimulating agents darbepoetin or erythropoietin to pret

38 epatocyte cultures were treated with the PKA-stimulating agents dibutyryl-cAMP (Bt2cAMP), forskolin,

39 Erythropoiesis-stimulating agents do not seem to benefit patients with

40 l roxadustat dose depended on erythropoiesis-stimulating agent dose at screening for patients already

41 xic conditions, and in responses to H(2)O(2)-stimulating agents, e.g. epidermal growth factor and lys

42 n the present study we demonstrate that cAMP-stimulating agents enhance the activity of the large-con

43 Erythropoiesis stimulating agent (ESA) administration may reduce mortal

44 onate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive

45 orse clinical outcomes in the erythropoiesis-stimulating agent (ESA) arm.

46 es to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, o

47 compared vadadustat with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa in patients wit

48 ior to current approaches for erythropoiesis stimulating agent (ESA) drug dosing guidelines or withou

49 ied for the first time to the erythropoiesis stimulating agent (ESA) products, which facilitated nove

50 ginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potent

51 l alternative to conventional erythropoiesis-stimulating agent (ESA) therapy.

52 In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodys

53 hemoglobin concentrations and erythropoietin stimulating agent (ESA) use among incident patients with

54 nsplant waitlist status); (2) erythropoietin-stimulating agent (ESA) use and related outcomes (anemia

55 de, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential therapy for anem

56 alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-

57 Poor response to erythropoiesis-stimulating agents (ESA) is associated with morbidity an

58 of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most stud

59 n-based phosphate binders and erythropoiesis-stimulating agents (ESA) to receive 24 weeks of FC or to

60 erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat a

61 on, intravenous [IV] iron, or erythropoiesis stimulating agent [ESA]) at enrollment in the CKDopps.

62 estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in hemodi

63 se; it is mainly treated with erythropoiesis-stimulating agents (ESAs) and iron.

64 y, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.

65 The optimal use of erythropoiesis-stimulating agents (ESAs) and parenteral iron in managin

66 Erythropoiesis-stimulating agents (ESAs) are commonly used to treat ane

67 sion dependence (RBC-TD), and erythropoiesis-stimulating agents (ESAs) are the mainstay of therapy in

68 Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treat

69 ialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammat

70 on alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the

71 -placebo-controlled trials of erythropoiesis-stimulating agents (ESAs) comparing lower and higher hem

72 icans require higher doses of erythropoiesis-stimulating agents (ESAs) during dialysis to manage anem

73 The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin

74 The efficacy of erythropoietin-stimulating agents (ESAs) for improving health-related q

75 ve to conventional injectable erythropoietin-stimulating agents (ESAs) for the treatment of anemia in

76 Erythropoiesis stimulating agents (ESAs) have been reported to activate

77 venous (IV) iron products and erythropoiesis-stimulating agents (ESAs) have resulted in many patients

78 Small studies showed that erythropoiesis-stimulating agents (ESAs) improve subjective measures of

79 nges to dosing guidelines for erythropoiesis-stimulating agents (ESAs) in 2011 appear to have influen

80 rials assessing the effect of erythropoiesis-stimulating agents (ESAs) in critically ill trauma patie

81 rs (PHIs) are as effective as erythropoiesis-stimulating agents (ESAs) in increasing hemoglobin level

82 ciency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with

83 gy recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.

84 or a high cumulative dose of erythropoiesis-stimulating agents (ESAs) may contribute to cardiovascul

85 hes to anemia management with erythropoiesis-stimulating agents (ESAs) may result in undesired patter

86 boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse even

87 netic markers associated with erythropoiesis-stimulating agents (ESAs) response in LR-MDS.

88 The use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and dar

89 Erythropoietin-stimulating agents (ESAs) were originally designed to re

90 Erythropoiesis-stimulating agents (ESAs) were prescribed to 92% of pati

91 factor support was required; erythropoiesis-stimulating agents (ESAs) were used at the investigator'

92 a are frequently treated with erythropoiesis-stimulating agents (ESAs), which are dynamically dosed i

93 dromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of appro

94 ding to or are ineligible for erythropoiesis-stimulating agents (ESAs).

95 of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs).

96 and blunting the activity of erythropoiesis stimulating agents (ESAs).

97 ermine the patterns of use of erythropoiesis-stimulating agents (ESAs).

98 ith RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).

99 of potential harm from using erythropoiesis-stimulating agents (ESAs).

100 pportive care with or without erythropoiesis-stimulating agents for patients with low-risk MDS to hyp

101 ted by cAMP analogues and the adenyl cyclase-stimulating agent forskolin.

102 The granulopoiesis-stimulating agents (GSAs) have been effectively utilized

103 tients who were not receiving erythropoiesis-stimulating agents, hemoglobin increased 0.62 +/- 1.02 g

104 g patients who were receiving erythropoiesis-stimulating agents, hemoglobin increased 1.16 +/- 1.49 g

105 of restrictions on the use of erythropoiesis-stimulating agents in cancer may impact blood availabili

106 Immunosuppressants, erythropoiesis-stimulating agents in combination with granulocyte colon

107 recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate ane

108 to potentiate the response to erythropoiesis-stimulating agents in patients with renal anemia.

109 Trials of erythropoietin-stimulating agents in persons with kidney disease have a

110 possible beneficial effect of erythropoiesis-stimulating agents in the treatment of anemic heart fail

111 y does not support the use of erythropoiesis-stimulating agents in this subset of patients with anemi

112 odel after treatment with a variety of HIV-1 stimulating agents including PMA and TSA.

113 In response to the NADPH oxidase-stimulating agents including PMA, mBMMC and huMC produce

114 more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-indu

115 f expression in response to other cell death-stimulating agents, including ultraviolet radiation and

116 cAMP-stimulating agents increased U6 transcript levels, perha

117 ays, the development of novel erythropoiesis-stimulating agents, increasing evidence for EPO/EPOR cyt

118 This long-acting erythropoiesis-stimulating agent is as safe as conventional epoetin tre

119 0 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)

120 ologic features and dosing of erythropoiesis-stimulating agents may lead to cyclic pattern of hemoglo

121 ve control; P<0.001) and less erythropoietin-stimulating agent (median epoetin-equivalent units per w

122 with placebo (superiority) or erythropoiesis-stimulating agents (noninferiority).

123 reasons such as resistance to erythropoiesis-stimulating agents or cardiovascular instability.

124 vascular events compared with erythropoiesis-stimulating agents or placebo.

125 to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents o

126 nce status (KPS), exposure to erythropoiesis-stimulating agents, presence of central venous catheter

127 Erythropoietin-stimulating agent protocols are usually based on the res

128 Erythropoiesis stimulating agents remain the first-line treatment of an

129 Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and cha

130 Additionally, early erythropoiesis-stimulating agents (RR, 0.68 [95% CI, 0.57-0.83]; ARD, -

131 symptom in MDS, and although erythropoiesis-stimulating agents such as erythropoietin, lenalidomide,

132 ein was increased when combined with NK-cell-stimulating agents, such as poly I:C or recombinant mous

133 patients with lower-risk MDS, erythropoiesis stimulating agents, such as recombinant humanized erythr

134 to supraphysiologic levels of erythropoiesis-stimulating agent, supporting the hypothesis that hepcid

135 nd anti-D immunoglobulin, and thrombopoiesis-stimulating agents that are in early clinical developmen

136 th evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consiste

137 odysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally bec

138 ite the near universal use of erythropoiesis-stimulating agents, there are still occasions when patie

139 plastic syndromes, relying on erythropoiesis-stimulating agents to cope with anemia, and careful moni

140 And for emerging erythropoiesis-stimulating agents, to what extent do activities paralle

141 ion, and intravenous iron and erythropoietin-stimulating agent usage as prespecified secondary outcom

142 ed strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron admi

143 ng/ml or more without recent erythropoiesis-stimulating agent use were randomized (1:1) to oral dapr

144 reduces intravenous iron and erythropoietin-stimulating agent use while maintaining hemoglobin.

145 The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the high-dose group a

146 eatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an independent predic

147 oring therapeutic response to erythropoietic stimulating agents, while hyperchromic cells are an esse

148 atment options are limited to erythropoiesis-stimulating agents with or without intravenous iron ther

149 es have focused on the use of erythropoiesis-stimulating agents, with recent trials showing mixed res